Thermo Fisher Scientific
TMO
About: Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
Employees: 125,000
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
16% more call options, than puts
Call options by funds: $1.67B | Put options by funds: $1.43B
0.89% more ownership
Funds ownership: 87.86% [Q1] → 88.74% (+0.89%) [Q2]
5% less funds holding
Funds holding: 2,536 [Q1] → 2,414 (-122) [Q2]
14% less repeat investments, than reductions
Existing positions increased: 889 | Existing positions reduced: 1,034
18% less capital invested
Capital invested by funds: $165B [Q1] → $135B (-$29.7B) [Q2]
29% less first-time investments, than exits
New positions opened: 182 | Existing positions closed: 256
49% less funds holding in top 10
Funds holding in top 10: 83 [Q1] → 42 (-41) [Q2]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
|
Barclays
Luke Sergott
|
$550
|
Overweight
Upgraded
|
11 Sep 2025 |
|
UBS
Dan Leonard
|
$500
|
Neutral
Maintained
|
24 Jul 2025 |
|
Raymond James
Andrew Cooper
|
$535
|
Outperform
Reiterated
|
24 Jul 2025 |
|
Wells Fargo
Brandon Couillard
|
$565
|
Overweight
Maintained
|
24 Jul 2025 |
|
Baird
Catherine Schulte
|
$567
|
Outperform
Maintained
|
24 Jul 2025 |
|
Scotiabank
Sung Ji Nam
|
$590
|
Sector Outperform
Upgraded
|
11 Jul 2025 |
|
Evercore ISI Group
Vijay Kumar
|
$480
|
Outperform
Maintained
|
8 Jul 2025 |
Financial journalist opinion
Based on 18 articles about TMO published over the past 30 days
